CompletedPhase 4ACTRN12614000698673

In women with unexplained recurrent abortion, is prophylactic use of low dose aspirin and Calheparin more effective than no treatment in increasing the number of patients who complete their first trimester?


Sponsor

Ahmed Maged

Enrollment

180 participants

Start Date

Jun 1, 2011

Study Type

Interventional

Conditions

Summary

to study the effect of prophylactic use of low dose aspirin and heparin on patients with recurrent unexplained pregnancy loss Methods: prospective case control study conducted on 180 pregnant women randomized into 2equal groups. Group 1 received low dose aspirin 75 mg and heparin 5000 IU subcutaneous every 12 hours. Group 2 received no treatment


Eligibility

Sex: FemalesMin Age: 19 YearssMax Age: 40 Yearss

Inclusion Criteria2

  • Gestational age 5-7 weeks
  • history of three or more spontanous abortions without an obvious cause

Exclusion Criteria5

  • Participants with documented cause of recurrent abortion as antiphospholipid syndrome
  • history of thrombo-embolic manifestations
  • medical disorder as diabetes or hypertension
  • chronic disorder like renal cardiac or liver disease
  • those with structural anomalies of the uterus

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

180 pregnant women with history of recurrent unexplained pregnancy loss classified into 2 groups Group 1 included 90 women received low dose aspirin orally 75 mg once daily and heparin 5000 IU subcuta

180 pregnant women with history of recurrent unexplained pregnancy loss classified into 2 groups Group 1 included 90 women received low dose aspirin orally 75 mg once daily and heparin 5000 IU subcutaneous every 12 hours started at 8 weeks gestation till the end of 12th week. Group 2 included 90 women received no treatment. Monitoring adherence to treatment was done by counting drug tablets return and counting number of used syringes every 2 weeks


Locations(1)

Cairo, Egypt

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12614000698673